These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15051302)

  • 1. Merck Sharp and Dohme versus Laporte.
    Honig P
    Lancet; 2004 Mar; 363(9414):1079-80. PubMed ID: 15051302
    [No Abstract]   [Full Text] [Related]  

  • 2. Merck Sharpe and Dohme versus Laporte.
    Laporte JR
    Lancet; 2004 Jul 31-Aug 6; 364(9432):416. PubMed ID: 15288737
    [No Abstract]   [Full Text] [Related]  

  • 3. Spanish drug editor wins case brought by Merck, Sharp Dohme.
    Gibson L
    BMJ; 2004 Feb; 328(7435):307. PubMed ID: 14764479
    [No Abstract]   [Full Text] [Related]  

  • 4. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 5. Manipulating a journal article.
    N Y Times Web; 2005 Dec; ():WK11. PubMed ID: 16453395
    [No Abstract]   [Full Text] [Related]  

  • 6. Merck accused of disguising its role in research.
    Cressey D
    Nature; 2008 Apr; 452(7189):791. PubMed ID: 18431823
    [No Abstract]   [Full Text] [Related]  

  • 7. Merck VIOXX "warning" is questioned.
    Allen TS; Henderson JH
    Tex Med; 2005 May; 101(5):5-6. PubMed ID: 15948521
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence in Vioxx suits shows intervention by Merck officials.
    Berenson A
    N Y Times Web; 2005 Apr; ():A1, A32. PubMed ID: 15940861
    [No Abstract]   [Full Text] [Related]  

  • 9. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 10. Will Merck survive Vioxx?
    Simons J; Stipp D
    Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
    [No Abstract]   [Full Text] [Related]  

  • 11. Painkiller verdict shows mistrust of Merck.
    Khamsi R
    Nature; 2005 Aug; 436(7054):1070. PubMed ID: 16121136
    [No Abstract]   [Full Text] [Related]  

  • 12. Rofecoxib (Vioxx) voluntarily withdrawn from market.
    Sibbald B
    CMAJ; 2004 Oct; 171(9):1027-8. PubMed ID: 15505253
    [No Abstract]   [Full Text] [Related]  

  • 13. NEJM editor gives pretrial evidence in Vioxx case.
    Tanne JH
    BMJ; 2006 Feb; 332(7536):255. PubMed ID: 16455704
    [No Abstract]   [Full Text] [Related]  

  • 14. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
    Moynihan R
    BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350
    [No Abstract]   [Full Text] [Related]  

  • 15. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 16. Failing the public health--rofecoxib, Merck, and the FDA.
    Topol EJ
    N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
    [No Abstract]   [Full Text] [Related]  

  • 17. The preacher who's raising hell with Merck.
    Parloff R
    Fortune; 2005 Aug; 152(3):20. PubMed ID: 16097189
    [No Abstract]   [Full Text] [Related]  

  • 18. Despite warnings, drug giant took long path to Vioxx recall.
    Berenson A; Harris G; Meier B; Pollack A
    N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
    [No Abstract]   [Full Text] [Related]  

  • 19. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 20. Merck withdraws arthritis drug worldwide.
    Singh D
    BMJ; 2004 Oct; 329(7470):816. PubMed ID: 15472245
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.